Neuroendocrine tumor and carcinoid tumor
Conditions
Interventions
None listed
Sponsors
Department of Nuclear Medicine, National Center for Global Health and Medicine, Tokyo, Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients having neuroendocrine tumor with somatostatin receptor confirmed histologically. Patients having known residual tumor or metastasis by CT scan etc. that can be detected with OctreoScan and FDGPET. Patients who can provide enough medical information including imaging data, histopathology, and treatment history, also can halt somatostatin specific therapy 3 weeks before OctreoScan. Patients with grade 0-2 of performance status(ECOG/WHO), that is from asymptomatic to symptomatic but less than 50% in bed during the day. This clinical research is not sponsored by company etc. Those who want to enter the study must pay by themselves, and sign the informed consent. Please check the information in our homepage.
Exclusion criteria
Exclusion criteria: Patients having double cancer, or other serious diseases or condition cannot enter the study. Patients who need immediate surgical procedures or radiation therapy cannot enter the study. Pregnant patients cannot enter the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The target lesion will be determined by history, previous imaging studies, and by CT images at FDGPET/CT. Then, lesion based sensitivity, and the grade of tracer uptake by lesion will be assessed with FDGPET and OctreoScan. | — |
Countries
Japan
Contacts
Public ContactKUBOTA Kazuo
National Center for Global Health and Medicine, Tokyo, Japan Department of Nuclear Medicine
Outcome results
None listed